Non-Hodgkin Lymphoma

Conference Coverage

`Remarkable’: CAR T therapy for CLL/SLL

Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...

Pages